Literature DB >> 24140010

Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome: comparison of the results with that of multiple sclerosis patients.

Bilge Piri Cinar1, Serkan Ozakbas, Egemen Idiman.   

Abstract

OBJECTIVES: The aim of the present study was to examine the changes in the measurement of functions during and after pulse methylprednisolone (MP) treatment during a clinically isolated syndrome (CIS) attack, using the multiple sclerosis functional composite (MSFC) and Expanded Disability Status Scale (EDSS), and to compare the results with that of MS patients. PATIENTS AND
METHOD: The present study included 44 patients with CIS and 26 patients with clinically definite multiple sclerosis (MS), as the control group. All patients were having an acute attack and were treated with 1000-mg intravenous methylprednisolone. The scales were administered before-and after-treatment, and at 30 days after treatment.
RESULTS: A 5-days treatment was adequate in 36.9% of CIS patients and 62.5% of MS patients (p=0.003). A moderate correlation was found between Auditory Consonant Trigram Test (ACT) and paced auditory serial addition test in CIS patients before-treatment. A poor correlation was found between EDSS scores and ACT in CIS patients at all measurement periods. The level of correlation between EDSS and ACT scores was similar in MS patients.
CONCLUSION: Although MS and CIS patients show similar response to corticosteroid treatment and had similar fatigue characteristics, overall cognitive functioning was better in CIS patients.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Clinically isolated syndrome; Cognition; Multiple sclerosis; Prognosis; Treatment

Mesh:

Substances:

Year:  2013        PMID: 24140010     DOI: 10.1016/j.clineuro.2013.09.003

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  3 in total

1.  Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial.

Authors:  Regina Berkovich; Rohit Bakshi; Lilyana Amezcua; Robert C Axtell; Steven Y Cen; Shahamat Tauhid; Mohit Neema; Lawrence Steinman
Journal:  Ther Adv Neurol Disord       Date:  2016-10-19       Impact factor: 6.570

2.  Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis.

Authors:  Serkan Özakbaş; Bilge Piri Çinar; Didem Öz; Görkem Kösehasanoğullari; Behice Bircan Kurşun; Turhan Kahraman
Journal:  Noro Psikiyatr Ars       Date:  2018-07-06       Impact factor: 1.339

3.  Multidisciplinary rehabilitation and steroids in the management of multiple sclerosis relapses: a randomized controlled trial.

Authors:  Una Nedeljkovic; Jelena Dackovic; Darija Kisic Tepavcevic; Irena Dujmovic Basuroski; Sarlota Mesaros; Tatjana Pekmezovic; Jelena Drulovic
Journal:  Arch Med Sci       Date:  2015-03-18       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.